A nitrogen-containing bridged ring compound and its preparation method and application
By designing new compounds, the selectivity and efficacy of OX2R antagonists are improved, and the problems of low selectivity and insufficient safety of OX2R antagonists in the prior art are solved, and effective regulation of the sleep-wake cycle and safe drugs are achieved. Effect.
Patent Information
- Application Number
- CN202411079360.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-07
AI Technical Summary
The existing OX2R antagonists are low selectivity, resulting in improper regulation of REM and NREM sleep time, increasing the risk of drowsiness, and the safety and efficacy have not yet reached the ideal level.
A novel compound was developed that significantly improves the selectivity for OX2R through specific structural designs, and improves the efficacy and safety of the compound by optimizing the synthesis route and reaction conditions.
The OX2R antagonist with high selectivity and high efficacy has been achieved, which can effectively regulate the sleep-wake cycle, reduce the risk of drowsiness, and significantly improve safety.
Smart Images

Figure SMS_6 
Figure SMS_7 
Figure SMS_8
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a class of nitrogen-bridged ring-containing compounds and preparation methods and applications thereof. Background Art
[0002] Orexin is a neuropeptide discovered in 1998. It is synthesized and secreted by the lateral hypothalamic orexin neurons. There are two types, OrexinA and OrexinB. Orexin A contains 33 amino acids and Orexin B contains 28 amino acids. They act on the G-protein-coupled orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R) receptor subtypes, respectively.
[0003] OX1R and OX2R are widely expressed in the central nervous system and have complex relationships with other neuropeptides that affect feeding. Rodents injected with orexin intraperitoneally have prolonged wakefulness (Piper et al. J. Neurosci. 2000 12.726-730), OX2R damage or mutation leads to long-term sleep in dogs (lin et al. Cell 1999, 365-376), and insufficient orexin signals in cerebrospinal fluid will cause long-term narcolepsy in humans. All of these indicate that wakefulness and sleep can be regulated by regulating the two receptors. OX1R and OX2R play different roles in controlling non-rapid eye movement sleep (NREM, deep sleep) and rapid eye movement sleep (REM, brain activity is the same as when awake). OX2R is a key receptor for regulating wakefulness and NREM sleep, while REM sleep is controlled by two receptor subtypes. OX2R plays a dominant role in regulating sleep, while OX1R alone contributes little to sleep induction, but works synergistically with OX2R to regulate REM sleep.
[0004] Orexin receptor antagonists are divided into selective OX1R antagonists, selective OX2R antagonists and dual OX1 / 2R antagonists according to their binding affinity. Dual OX1 / 2R antagonists from multiple companies have been launched on the market, including Suvorexant from Merck & Co, Lemborexant from Eisai, and daridorexant from Johnson & Johnson. However, acting on OX1R will change the normal physiological structure of REM and NREM, that is, sacrificing NREM time, prolonging REM time, and thus increasing the risk of sleepiness.
[0005] Currently, the only selective antagonist is Johnson & Johnson's Seltorexant in phase III clinical trials, with indications for major depression, insomnia, etc. Although it shows certain selectivity for OX1R and OX2R, its selectivity still needs to be improved.
[0006] Therefore, there is an urgent need in the art for an OX2R antagonist with high selectivity and safety. Summary of the invention
[0007] In order to solve the above problems, the present invention provides an OX2R antagonist with high antagonist selectivity, high efficacy and high safety.
[0008] In the first aspect of the present invention, there is provided a compound as represented by formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, wherein b is selected from 1, 2 or 3;
[0009] a, c, d and e are each independently selected from 0, 1, 2 or 3, and 2 ≤ a+c+d+e ≤ 6;
[0010] R1, R2, R3, R4, R5 and R6 are each independently selected from the group consisting of H, hydroxyl, C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy, or R1 and R2 on the same carbon together form =O, or R3 and R4 on the same carbon together form =O, or R5 and R6 on the same carbon together form =O;
[0011] Ar1 is selected from the following group: C 6-10 aryl, 5-6 membered heteroaryl, and the phenyl and 5-6 membered heteroaryl are optionally substituted by 1, 2, 3 or 4 R a replace;
[0012] R a Selected from the group consisting of H, D, nitro, C 1-4 Alkyl, C 1-4 Alkoxy, halogen, cyano, -S(O)2(C 1-4 Alkyl), C 1-4 Haloalkyl, -NH(C 1-4 Alkyl), -N(C 1-4 alkyl)2, 5-7 membered heteroaryl;
[0013] Ar2 is selected from the group consisting of 5-6 membered heteroaryl, 9-10 membered heteroaryl, and the 5-6 membered heteroaryl and 9-10 membered heteroaryl are optionally substituted by 1, 2 or 3 R b replace;
[0014] R b Selected from the group consisting of H, D, halogen, hydroxy, cyano, nitro, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, 3-7 membered cycloalkyl.
[0015] In another preferred embodiment, the heteroaryl group is an aromatic cyclic group containing 1, 2, 3 or 4 heteroatoms selected from N, O or S in the ring skeleton.
[0016] In another preferred embodiment, the heteroaryl group is a monocyclic ring or a condensed ring.
[0017] In another preferred example, said 2 ≤a+c+d+e ≤ 4.
[0018] In another preferred embodiment, a+c+d+e=2.
[0019] In another preferred embodiment, a and c are 1.
[0020] In another preferred embodiment, said d and e are 0.
[0021] In another preferred embodiment, a and d are 1.
[0022] In another preferred embodiment, said e and c are 0.
[0023] In another preferred embodiment, b is 1 or 2.
[0024] In a preferred embodiment, R1, R2, R3, R4, R5 and R6 are all H.
[0025] In a preferred example, Ar1 is a substituted or unsubstituted group selected from the group consisting of phenyl, naphthyl, furan, thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, thiazole, imidazole, pyridine, pyridazine, pyrimidine, and pyrazine.
[0026] In a preferred embodiment, the R a Selected from the following group: H, D, C 1-4 Alkyl, C 1-3 Alkoxy, halogen, cyano, -S(O)2(C 1-3 Alkyl), C 1-3 Fluorinated alkyl, -NH(C 1-3 Alkyl), -N(C 1-3 alkyl) 2, 5-6 membered nitrogen-containing heteroaryl.
[0027] In another preferred embodiment, the R a Selected from the following group: H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, F, Cl, Br, cyano, -S(O)2-CH3, CF3, -N(CH3)2, 1,2,3-triazole, 1,2,4-triazole, pyridine, pyrimidine.
[0028] In a preferred example, Ar2 is a substituted or unsubstituted group selected from the following group: a 5-6 membered heteroaryl group, a benzo 5-6 membered heteroaryl group.
[0029] In another preferred embodiment, Ar2 is a substituted or unsubstituted group selected from the following group: furan, thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, thiazole, imidazole, pyridine, pyridazine, pyrimidine, pyrazine, benzofuran, benzothiophene, benzopyrrole, benzoxazole, benzothiazole, benzimidazole, benzopyridine, benzopyrimidine, and benzopyrazine.
[0030] In a preferred embodiment, the R b Selected from the group consisting of H, D, halogen, hydroxy, cyano, nitro, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Fluorinated alkyl, 3-5 membered cycloalkyl.
[0031] In another preferred embodiment, the R b Selected from the following group: H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, F, Cl, Br, I, hydroxyl, cyano, nitro, -CF3, cyclopropyl, cyclobutyl, cyclopentyl.
[0032] In a preferred embodiment, the compound has a structure represented by formula (II) or formula (III): Wherein, b is 1 or 2;
[0033] Ar1 and Ar2 are as defined in claim 1.
[0034] In another preferred embodiment, the compound has a structure shown in formula (II-1) or (II-2): wherein Ar1 and Ar2 are as defined above.
[0035] In another preferred embodiment, the compound has a structure shown in formula (IV) or formula (V): Wherein, m is 1 or 2;
[0036] b is 1 or 2;
[0037] Each R a are independently halogen or 5-6 membered nitrogen-containing heteroaryl;
[0038] Ar2 is as defined above.
[0039] In another preferred embodiment, the compound has a structure shown in formula (IV-1) or formula (IV-2): Wherein, m is 1 or 2;
[0040] Each R aare independently halogen or 5-6 membered nitrogen-containing heteroaryl;
[0041] Ar2 is as defined above.
[0042] In another preferred embodiment, the compound has a structure represented by formula (VI) or formula (VII): Wherein, b is 1 or 2;
[0043] n is 2 or 3; each R b Independently selected from the following group: H, methoxy, ethoxy, F, Cl, Br, I, hydroxyl, cyano, nitro, -CF3.
[0044] In another preferred embodiment, the compound has a structure shown in formula (VI-1) or formula (VI-2): Wherein, n is 2 or 3;
[0045] Each R b Independently selected from the following group: H, methoxy, ethoxy, F, Cl, Br, I, hydroxyl, cyano, nitro, -CF3.
[0046] In another preferred embodiment, the compound has a structure shown in formula (VIII) or formula (IX): Wherein, b is 1 or 2;
[0047] R b Selected from the group consisting of H, D, halogen, hydroxy, cyano, nitro, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Fluorinated alkyl, 3-5 membered cycloalkyl.
[0048] In another preferred embodiment, the compound has a structure represented by formula (VIII-1) or formula (VIII-2): Among them, R b Selected from the group consisting of H, D, halogen, hydroxy, cyano, nitro, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Fluorinated alkyl, 3-5 membered cycloalkyl.
[0049] In a preferred embodiment, the compound is selected from the following group: .
[0050] The second aspect of the present invention provides a pharmaceutical composition, comprising:
[0051] (i) the compound according to the first aspect of the present invention, its stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug; and
[0052] (ii) a pharmaceutically acceptable carrier, adjuvant or vehicle.
[0053] The third aspect of the present invention provides the use of the compound as described in the first aspect of the present invention, its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, or the pharmaceutical composition as described in the second aspect of the present invention, characterized in that it is used for the preparation of drugs for treating and / or preventing diseases related to orexin.
[0054] In another preferred embodiment, the disease associated with orexin is selected from the following group: sleep-wake cycle disorder, insomnia, restless legs syndrome, jet lag syndrome, sleep disturbance, depression, Alzheimer's disease, sleep disorders secondary to the following diseases: neurotic disorders, mania, depression, bipolar disorder, schizophrenia, pain syndrome, fibromyalgia, neuropathic pain, tension, Parkinson's disease, Tourette's syndrome, anxiety, delirium, dementia, overweight or obesity, and conditions related to overweight or obesity, insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina pectoris, hypertension, dyspnea, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins, osteoarthritis, hypertension, tachycardia, arrhythmia, angina pectoris, acute heart failure, ulcer, irritable bowel syndrome, diarrhea, gastroesophageal reflux.
[0055] In another preferred embodiment, the disease related to orexin is selected from the group consisting of insomnia, depression, and Alzheimer's disease.
[0056] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. DETAILED DESCRIPTION
[0057] After long-term and in-depth research and extensive screening, the inventors have developed for the first time an OX2R antagonist with high antagonist selectivity, high efficacy and high safety. Based on this, the inventors have completed the present invention.
[0058] the term
[0059] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".
[0060] As used herein, the term "alkyl" refers to a monovalent straight or branched chain saturated hydrocarbon group consisting of carbon and hydrogen atoms, for example, "C 1-6 "Alkyl" means an alkyl group having 1-6 (e.g., 1, 2, 3, 4, 5 or 6) carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl, etc. In the present application, alkyl groups are also intended to include deuterated alkyl groups, and examples of deuterated alkyl groups include, but are not limited to, CD3, CD2CD3, CD2CD2CD3.
[0061] As used herein, the term "cycloalkyl" refers to a monovalent saturated carbocyclic group consisting of carbon and hydrogen atoms, such as "C 3-8 "Cycloalkyl" refers to a cycloalkyl group containing 3 to 8 (e.g., 3, 4, 5, 6, 7 or 8) carbon atoms, preferably C 3-6 Cycloalkyl. The cycloalkyl group may be a monocyclic ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or the like, or a bicyclic ring, such as a fused ring, a bridged ring or a spiro ring.
[0062] As used herein, the term "alkoxy" refers to an -O-alkyl group, wherein examples of alkoxy include, but are not limited to, methoxy, ethoxy, isopropoxy, tert-butoxy, and the like.
[0063] As used herein, the term "hydroxyalkyl" refers to an alkyl group containing one or more hydroxyl groups, and the definition of alkyl is as described above. Examples of hydroxyalkyl groups include, but are not limited to, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, and the like.
[0064] As used herein, the term "halogen" refers to F, Cl, Br, I and isotopes thereof, including but not limited to F, 18 F, Cl, 32 Cl, Br, I.
[0065] As used herein, the term "nitro" refers to -NO2.
[0066] As used herein, the term "haloalkyl" refers to a group in which one or more hydrogen atoms in the alkyl group described above are replaced by the same or different halogen atoms. 1-6 The "alkyl" is preferably a halogenated C1-4 alkyl, examples of which include, but are not limited to, -CH2Cl, -CH2CF3, -CH2CCl3, perfluoroalkyl (e.g., -CF3-, -CF2CF3), and the like.
[0067] As used herein, the term "aryl" refers to an aromatic cyclic hydrocarbon group (including a monocyclic, bicyclic or polycyclic group), for example, 6-12 "Aryl" refers to an aromatic cyclic hydrocarbon group with 6-12 (6, 7, 8, 9, 10, 11 or 12) ring carbon atoms. Among them, it contains two or more aromatic rings (such as bicyclic rings, etc.), and the aromatic rings of the aryl group can be connected by a single bond (such as biphenyl) or fused (such as naphthalene, anthracene, etc.). Examples of aryl (especially monocyclic and bicyclic groups) include but are not limited to: phenyl, biphenyl or naphthyl. The aryl group can be fused with the heterocyclic group through a single bond or any two adjacent ring carbon atoms, for example: benzotetrahydrofuranyl, benzotetrahydropyranyl, benzodioxanyl, wait.
[0068] As used herein, the term "heteroaryl" refers to an aromatic cyclic group (including monocyclic, bicyclic or polycyclic groups) whose ring skeleton contains 1, 2, 3 or 4 heteroatoms selected from N, S or O, for example, "5-12 membered heteroaryl" refers to a monocyclic, bicyclic or tricyclic group having 5 to 12 (5, 6, 7, 8, 9, 10, 11 or 12) ring atoms. Examples of heteroaryl groups include, but are not limited to, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, thienyl, furanyl, pyranyl, pyridinyl, pyrrolyl, pyrazolyl, pyrimidinyl, quinolyl, isoquinolyl, benzofuranyl, benzothiophenyl, benzothiopyranyl, benzimidazolyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzopyranyl, indolyl, isoindolyl, triazolyl, triazine, quinoxalinyl, purinyl, quinazolinyl, quinolizinyl, naphthyridinyl, pteridinyl, carbazolyl, azaquinyl, diazepine, acridinyl, and the like.
[0069] As used herein, the term "substituted" refers to one or more hydrogen atoms on a specific group being replaced by a specific substituent. The specific substituent is a substituent described above or a substituent appearing in the embodiments. Unless otherwise specified, a substituted group may have a substituent selected from a specific group at any substitutable site of the group, and the substituent may be the same or different at each position. It will be understood by those skilled in the art that the combinations of substituents contemplated by the present invention are those that are stable or chemically feasible.
[0070] Unless otherwise specified, the groups of the present invention may be substituted by substituents selected from the group consisting of D, halogen, cyano, nitro, hydroxyl, amino, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, 3-12 membered heterocyclic group, C3-C 12 Cycloalkyl, 5-10 membered heteroaryl and C6-C 10 Aryl.
[0071] As used herein, "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where said event or circumstance does not occur.
[0072] Abbreviations
[0073]
[0074] Active ingredients
[0075] As used herein, "compound of the present invention" refers to the compound represented by formula (I), and also includes its stereoisomers, optical isomers, pharmaceutically acceptable salts, crystal forms, isotopic derivatives, prodrugs, metabolites, solvates or hydrates thereof.
[0076] Unless otherwise specified, the structural formulas described in the present invention are intended to include all stereoisomers (such as cis-trans isomers, enantiomers, diastereomers and conformational isomers): R, S configurations containing asymmetric centers, (Z), (E) isomers of double bonds, cis-trans isomers of cycloalkanes, etc. Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their enantiomers, diastereomers or conformational isomers are all within the scope of the present invention.
[0077] The compounds of the present invention may contain cis-trans isomers, one or more chiral carbon atoms, and thus may produce stereoisomeric forms of cis-trans isomers, chiral isomers, enantiomers, diastereomers and other combinations. Cis-trans isomerism refers to the diastereoisomerism phenomenon that occurs due to the restriction of free rotation in the compound molecule, which causes the different arrangements of various groups in space. This restriction is generally caused by the presence of functional groups that cannot rotate freely in the structure of organic compounds, such as C=C double bonds, C=N double bonds, C=S double bonds, N=N double bonds, heterocycles or cycloalkanes. Organic molecules containing such isomers, such as olefins, azo compounds, cycloalkanes, etc., are considered cis-trans isomers. The cis form refers to the same ligands in adjacent positions, generally represented by "cis" or "cis-"; the trans form refers to the same ligands in diagonal positions, generally represented by "trans" or "trans-". Each chiral carbon atom can be defined as (R)- or (S)- based on stereochemistry. The present invention is intended to include all possible isomers, as well as racemates and optically pure forms thereof. The compounds of the present invention may be prepared using racemates, cis-trans isomers, chiral isomers, diastereomers or enantiomers as starting materials or intermediates. Optically active isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as crystallization and chiral chromatography.
[0078] Conventional techniques for preparing / isolating individual optical isomers (ie, cis-trans and chiral isomers) include chiral synthesis from appropriate cis-trans or optically pure precursors, or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high performance liquid chromatography.
[0079] If a synthesis of a specific stereoisomer of the compound of the present invention is to be designed, it can be prepared by asymmetric synthesis, or derivatized with a chiral auxiliary, the resulting stereo mixture can be separated, and then the chiral auxiliary can be removed to obtain a pure cis-trans monomer, a chiral monomer or a mixed stereo monomer. If the molecule contains a cis-trans isomeric center, it can be purified by column chromatography (normal phase silica gel column or reverse phase high performance liquid preparation) to obtain a pure cis product or trans product; in addition, if the molecule contains a basic functional group, such as an amino acid, or an acidic functional group, such as a carboxyl group, it can be used with a suitable optically active acid or base to form a diastereomeric salt, and then separated by conventional means such as fractional crystallization or chromatography, and then a pure enantiomer is obtained.
[0080] The present invention also includes isotopically labeled compounds (i.e., isotopic derivatives) that are equivalent to the original compounds disclosed herein. However, in practice, it is common for one or more atoms to be replaced by atoms having a different atomic mass or mass number than the original atoms. Examples of isotopes in the isotopic derivatives of the present invention include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine isotopes, such as 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. The isotopic derivatives of the compounds of the present invention are all within the protection scope of the present invention. 3 H-labeled compounds and 14 C-labeled compounds are useful in drug and substrate tissue distribution experiments. 3 H) and carbon-14 (i.e. 14 C) labeled compounds are easier to prepare and detect, and are the first choice among isotopes. In addition, heavier isotope substitutions such as deuterium, i.e. 2 H, due to its good metabolic stability in certain therapies has advantages, such as increasing half-life or reducing dosage in vivo, therefore, in some cases, it can be preferred. Isotope-labeled compounds can be prepared by general methods by replacing readily available isotope-labeled reagents with non-isotopic reagents using the schemes disclosed in the examples.
[0081] As used herein, the term "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0082] "Pharmaceutically acceptable acid addition salts" refer to salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without other side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, and the like; organic acid salts include, but are not limited to, formates, acetates, 2,2-dichloroacetates, trifluoroacetates, propionates, caproates, caprylates, decanoates, undecylenates, glycolates, gluconates, lactates, sebacates, adipates, glutarates, malonates, oxalates, maleates, succinates, fumarates, tartrates, citrates, palmitates, stearates, oleates, cinnamates, laurates, malates, glutamate, pyroglutamate, aspartate, benzoates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, alginate, ascorbate, salicylates, 4-aminosalicylates, naphthalene disulfonates, and the like. These salts may be prepared by methods known in the art.
[0083] "Pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic base or an organic base that can maintain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Preferred inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts, and magnesium salts. The salt derived from organic base includes but is not limited to the following salt: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins etc. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the profession.
[0084] The metabolites of the compound represented by formula (I) and its pharmaceutically acceptable salts, and the prodrugs that can be converted into the compound represented by formula (I) and its pharmaceutically acceptable salts in vivo are also included in the protection scope of the present invention.
[0085] As used herein, the term "solvate" refers to a complex formed by coordination of the compound represented by formula (I) with solvent molecules in a specific ratio.
[0086] As used herein, the term "hydrate" refers to a complex formed by the compound represented by formula (I) and water molecules coordinated to form a specific ratio.
[0087] As described herein, the compounds of the present invention can be substituted with any number of substituents or functional groups to expand their scope. In general, the term "substituted" refers to replacing hydrogen radicals with specified structural substituents. When multiple positions in a specific structure are substituted with multiple specific substituents, the substituents can be the same or different at each position. The term "substituted" used herein includes all allowed organic group substitutions. In a broad sense, allowed substituents include non-cyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic organic groups. Herein, heteroatom nitrogen can have hydrogen substituents or any allowed organic groups described above to supplement its valence. In addition, the present invention is not intended to limit the allowed substitution of organic groups in any way. The present invention believes that the combination of substituents and variable groups is good in the treatment of diseases in the form of stable compounds. The term "stable" here refers to a stable compound that is tested for a long enough time to maintain the integrity of the compound structure, preferably for a long enough time, and is used for the above purposes herein.
[0088] Pharmaceutical compositions and methods of administration
[0089] Since the compounds of the present invention can selectively inhibit orexin receptor 2 (OX2R), and are used to treat diseases such as sleep-wake cycle disorders, insomnia, restless legs syndrome, jet lag syndrome, depression, Alzheimer's disease, etc. Therefore, the compounds of the present invention and their stereoisomers, optical isomers, pharmaceutically acceptable salts, crystal forms, isotope derivatives, prodrugs, metabolites, solvates or hydrates thereof, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredients can be used to prevent and / or treat (stabilize, alleviate or cure) orexin-related diseases (sleep-wake cycle disorders, insomnia, restless legs syndrome, jet lag syndrome, depression, Alzheimer's disease, etc.).
[0090] The pharmaceutical composition of the present invention comprises a safe and effective amount of the compound of the present invention and a pharmaceutically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, and more preferably, contains 10-200 mg of the compound of the present invention per dose. Preferably, the "one dose" is a capsule or tablet.
[0091] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as Tween®), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0092] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administration methods include, but are not limited to, oral administration and parenteral administration (intravenous, intramuscular or subcutaneous administration).
[0093] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0094] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.
[0095] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
[0096] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0097] In addition to the active ingredients, suspensions may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances.
[0098] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0099] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.
[0100] The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
[0101] When administered in combination, the pharmaceutical composition may further include one or more (2, 3, 4, or more) other pharmaceutically acceptable compounds. One or more (2, 3, 4, or more) of the other pharmaceutically acceptable compounds may be used simultaneously, separately, or sequentially with the compound of the present invention to prevent and / or treat diseases related to orexin.
[0102] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is administered to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage, and for a person weighing 60 kg, the daily dosage is usually 1-2000 mg, preferably 20-500 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill of a skilled physician.
[0103] Preparation method
[0104] 1) Preparation method 1
[0105]
[0106] Step 1:
[0107] Using dichloromethane as solvent, aromatic carboxylic acid (Ar1-COOH) reacts with oxalyl chloride in DMF to obtain the corresponding acyl chloride;
[0108] Using NN-diisopropylethylamine (DIEA) as a base, the above acid chloride reacts with the mono-Boc-protected bridged ring diamine compound A in dichloromethane to obtain the corresponding amide compound B.
[0109] or
[0110] With HATU as condensation agent, DMF as solvent and NN-diisopropylethylamine (DIEA) as base, aromatic carboxylic acid directly reacts with mono-Boc-protected bridged ring diamine compound A to obtain the corresponding amide compound B.
[0111] Step 2:
[0112] The obtained compound B was subjected to a deprotection reaction in a trifluoroacetic acid and dichloromethane system, and the obtained compound C was directly used in the next reaction.
[0113] Step 3:
[0114] Using cesium carbonate as a base and DMF as a solvent, the obtained compound C and Ar2 halide (Ar2-X, wherein X is a halogen) are directly subjected to SNAr reaction at a high temperature of 120°C and purified to obtain a candidate molecule D for biological testing, i.e., a compound of formula I.
[0115] 2) Preparation method 2
[0116]
[0117] Step 1:
[0118] Using cesium carbonate as a base and DMF as a solvent, a mono-Boc-protected bridged-ring diamine compound A and an Ar2 halide (Ar2-X, wherein X is a halogen) are directly subjected to a SNAr reaction at a high temperature of 120°C and purified to obtain a compound B'.
[0119] Step 2:
[0120] In a trifluoroacetic acid and dichloromethane system, compound B' was deprotected to obtain compound C', which was directly used in the next reaction.
[0121] Step 3:
[0122] Using dichloromethane as solvent, aromatic carboxylic acid (Ar1-COOH) reacts with oxalyl chloride in DMF to obtain the corresponding acyl chloride (Ar1-COCl);
[0123] The above acid chloride reacts with compound C' in dichloromethane using NN-diisopropylethylamine (DIEA) as a base to obtain a candidate molecule that can be directly used in biological testing.
[0124] or
[0125] Using HATU as a condensing agent, DMF as a solvent, NN-diisopropylethylamine (DIEA) as a base, aromatic carboxylic acid (Ar1-COOH) directly reacts with compound C' to obtain a candidate molecule D, i.e., a compound of formula I, which is directly used for biological testing.
[0126] The main advantage of the present invention is that the OX2R antagonist of the present invention has high selectivity for OX2R.
[0127] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for the unrecorded specific conditions in the following examples are usually carried out under normal conditions or under the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts.
[0128] Example 1
[0129] Compound 001: Preparation of (3-(4,6-dimethylpyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone
[0130]
[0131] first step
[0132]
[0133] At 25 °C, 2 mL of DMF was added to compound 001-01 (200.0 mg, 942.09 µmol, 1.0 eq), 1 (134.3 mg, 942.09 µmol, 1.0 eq), and Cs2CO3 (920.9 mg, 2.83 mmol, 3.0 eq). The reaction system was placed in a 120 °C oil bath and stirred for about 2 h. The reaction process was monitored by liquid quality control. After the reaction was completed and cooled to room temperature, about 30 mL of water was added to the reaction solution, and then extracted with EtOAc (50 mL) three times, the organic phases were combined and washed once with about 70 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was eluted with MPLC (ethyl acetate / petroleum ether = 0% - 50%) mobile phase gradient, and the obtained fractions were concentrated under reduced pressure to give compound 001-02 (colorless oil, 255 mg, yield 85.0%), MS (ESI, m / z): 319.41 [M+H] + .
[0134] Step 2
[0135]
[0136] At 25 °C, compound 001-02 (255 mg, 800.03 µmol, 1.0 eq) was dissolved in 2 mL of DCM, and 1 mL of TFA was added. The mixture was stirred for about 2 h, and the reaction process was monitored by TLC. After the reaction was completed, the solvent was removed by concentration under reduced pressure, and the residue 001-03 (248.7 mg) was directly used in the next step.
[0137] Step 3
[0138]
[0139] Compound 001-03 (248.7 mg, 748.20 µmol, 1.0 eq), 2 (155.0 mg, 748.20 µmol, 1.0 eq), HATU (341.4 mg, 897.84 µmol, 1.2 eq), and DIEA (483.5 mg, 3.74 mmol, 5.0 eq) were dissolved in 2 mL DMF at 25 °C. The reaction system was stirred at room temperature for 16 h, and the reaction process was monitored by liquid quality control. After the reaction was completed, about 50 mL of water was added to the reaction solution, and then extracted with EtOAc (30 mL) three times, the organic phases were combined and washed once with about 50 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by high pressure preparation to obtain product 001220.5 mg with a purity of 99.5%.
[0140] MS (ESI, m / z): 408.24 [M+H] + .
[0141] 1 H NMR (600 MHz, DMSO) δ 8.17 (s, 1H), 8.07 (s, 1H), 7.87-7.84 (m,1H), 7.78-7.65 (m, 1H), 7.50-7.39 (m, 1H), 6.69 (d, J = 24 Hz, 1H), 5.08 (br.s,1H), 4.90 (br.s, 1H), 3.58-2.93 (m, 4H), 2.39 (s, 3H), 2.36 (s, 3H), 2.01-1.76 (m, 4H)
[0142] Example 2
[0143] Compound 002: Preparation of (8-(4,6-dimethylpyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone
[0144]
[0145] first step
[0146]
[0147] At 25 °C, compound 002-01 (153.7 mg, 724.06 µmol, 1.0 eq), 1 (150.0 mg, 724.06 µmol, 1.0 eq), HATU (330.4 mg, 868.88 µmol, 1.2 eq), DIEA (467.9 mg, 3.62 mmol, 5.0 eq) were dissolved in 2 mL DMF, and the reaction system was stirred for 16 h. The reaction process was monitored by liquid chromatography-mass spectrometry. After the reaction was completed, about 50 mL of water was added to the reaction solution, and then extracted with EtOAc (30 mL) three times, the organic phases were combined and washed once with about 50 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was eluted with MPLC (0% - 50% ethyl acetate / petroleum ether) mobile phase gradient, and the obtained fractions were concentrated under reduced pressure to give compound 002-02 (colorless oil, 213 mg, yield 73.3%), MS (ESI, m / z): 402.34 [M + H] + .
[0148] Step 2
[0149]
[0150] At 25 °C, compound 002-02 (213 mg, 530.59 µmol, 1.0 eq) was dissolved in 2 mL of DCM, and 1 mL of TFA was added. The mixture was stirred for about 2 h, and the reaction process was monitored by TLC. After the reaction, the residue 002-03 (200 mg) was obtained by concentration under reduced pressure and used directly in the next step.
[0151] Step 3
[0152]
[0153] At 25 °C, compound 002-3 (100 mg, 240.76 µmol, 1.0 eq), 1 (34.3 mg, 240.76 µmol, 1.0 eq) and Cs2CO3 (392.2 mg, 1.20 mmol, 3.0 eq) were dissolved in 2 mL DMF, and the reaction system was placed in a 120 °C oil bath and stirred for about 2 h. The reaction process was monitored by liquid quality control. After the reaction was completed and cooled to room temperature, about 50 mL of water was added to the reaction solution, and then extracted with EtOAc (30 mL) three times, the organic phases were combined and washed once with about 50 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by high pressure preparation to obtain product 002 (44.7 mg, yield 45.6%).
[0154] MS (ESI, m / z): 408.29 [M+H] + .
[0155] 1 H NMR (300 MHz, DMSO) δ 8.17 (s, 1H), 8.07 (s, 1H), 7.88-7.84 (m, 1H), 7.74-7.66 (m, 1H), 7.51-7.40 (m, 1H), 6.69 (d, J = 30 Hz, 1H), 5.09 (br.s,1H), 4.91 (br.s, 1H), 3.53-2.94 (m, 4H), 2.39-2.36 (m, 6H), 2.01-1.76(m, 4H)
[0156] The following compounds were synthesized as above:
[0157]
[0158]
[0159] Example 3
[0160] Compound 009: Preparation of (6-(4,6-dimethylpyrimidin-2-yl)-3,6-diazabicyclo[3.1.1]nonan-3-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone
[0161]
[0162] first step
[0163]
[0164] At 25 °C, compound 009-01 (200.0 mg, 1.01 mmol, 1.0 eq), 1 (143.8 mg, 1.01 mmol, 1.0 eq), and Cs2CO3 (986.0 mg, 303 mmol, 3.0 eq) were dissolved in 2 mL DMF, and the reaction system was placed in a 120 °C oil bath and stirred for about 2 h. The reaction process was monitored by liquid quality control. After the reaction was completed and cooled to room temperature, about 50 mL of water was added to the reaction solution, and then extracted with EtOAc (70 mL) three times, the organic phases were combined and washed once with about 100 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography with a gradient elution of 0% - 30% ethyl acetate / petroleum ether mobile phase, and the obtained fractions were concentrated under reduced pressure to give compound 009-02 (white solid, 219 mg, yield 71.3%), MS (ESI, m / z): 305.40 [M+H] + .
[0165] Step 2
[0166]
[0167] At 25 °C, compound 009-02 (219 mg, 719.46 µmol, 1.0 eq) was dissolved in 2 mL of DCM, and 1 mL of TFA was added. The mixture was stirred for about 2 h, and the reaction process was monitored by TLC. After the reaction, the residue 009-03 (478 mg) was obtained by concentration under reduced pressure and used directly in the next step.
[0168] Step 3
[0169]
[0170] At 25 °C, compound 009-03 (147 mg, 719.46 µmol, 1.0 eq), 2 (149.1 mg, 719.46 µmol, 1.0 eq), HATU (328.3 mg, 863.36 µmol, 1.2 eq), and DIEA (464.9 mg, 3.60 mmol, 5.0 eq) were dissolved in 2 mL DMF, and the reaction system was stirred for 16 h. The reaction process was monitored by liquid quality control. After the reaction was completed, about 50 mL of water was added to the reaction solution, and then extracted with EtOAc (30 mL) three times, the organic phases were combined and washed once with about 50 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by high pressure preparation to obtain product 009 (33.2 mg, yield 18.3%, purity 99.0%).
[0171] MS (ESI, m / z): 394.26 [M+H] +
[0172] 1 H NMR (600 MHz, DMSO) δ 8.16 (s, 1H), 7.85-7.81(m, 1H), 7.71-7.62(m, 1H), 7.59 (s, 1H), 7.47-7.35 (m, 1H), 6.80-6.77 (m, 1H), 4.72 (br.s, 1H),4.01-3.92 (m, 2H), 3.77-3.63 (m, 2H), 3.38-3.29 (m, 1H), 2.80-2.73 (m, 1H),2.41-2.18 (m, 6H), 1.66-1.62 (m, 1H)
[0173] The following compounds were synthesized as above:
[0174]
[0175] Example 4
[0176] Compound 016: Preparation of (3-(4,6-dimethylpyrimidin-2-yl)-3,6-diazabicyclo[3.1.1]nonane-6-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone
[0177]
[0178] first step
[0179]
[0180] At 25 °C, compound 016-01 (143.6 mg, 724.06 µmol, 1.0 eq), 2 (150.0 mg, 724.06 µmol, 1.0 eq), HATU (330.4 mg, 868.88 µmol, 1.2 eq), DIEA (467.9 mg, 3.62 mmol, 5.0 eq) were dissolved in 2 mL DMF, and the reaction system was stirred for 16 h. The reaction process was monitored by liquid quality control. After the reaction was completed, about 50 mL of water was added to the reaction solution, and then extracted with EtOAc (30 mL) three times, the organic phases were combined and washed once with about 50 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography, eluting with a gradient of 0% - 50% ethyl acetate / petroleum ether mobile phase, and the resulting fractions were concentrated under reduced pressure to give compound 016-02 (colorless oil, 186 mg, yield 66.3%).
[0181] Step 2
[0182]
[0183] At 25 °C, compound 016-02 (186 mg, 480.1 µmol, 1.0 eq) was dissolved in 2 mL of DCM, and 1 mL of TFA was added. The mixture was stirred for about 2 h, and the reaction process was monitored by TLC. After the reaction, the residue 016-03 (138 mg) was obtained by concentration under reduced pressure and used directly in the next step.
[0184] Step 3
[0185]
[0186] At 25 °C, compound 016-03 (138 mg, 480.34 µmol, 1.0 eq), 1 (68.5 mg, 480.34 µmol, 1.0 eq) and Cs2CO3 (469.5 mg, 1.44 mmol, 3.0 eq) were placed in 2 mL DMF, and the reaction system was placed in a 120 °C oil bath and stirred for about 4 h. The reaction process was monitored by liquid quality control. After the reaction was completed and cooled to room temperature, about 50 mL of water was added to the reaction solution, and then extracted with EtOAc (30 mL) three times, the organic phases were combined and washed once with about 50 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by high pressure preparation to obtain product 01663.6 mg, with a yield of 47%).
[0187] MS (ESI, m / z): 394.22 [M+H] + .
[0188] 1 H NMR (600 MHz, DMSO) δ7.78-7.61(m, 3H), 7.51-7.44 (m, 1H), 6.79 (s,1H), 4.71-3.55 (m, 8H), 2.85-2.78 (m, 1H), 2.33-2.08 (m, 4H), 1.76-1.71 (m,1H)
[0189] Example 5
[0190] Compound 017: Preparation of ((1S,4S)-5-(4,6-dimethylpyrimidin-2-yl)-2,5-diazabicyclo[2.2.1]nonane-2-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone
[0191]
[0192] first step
[0193]
[0194] At 25 °C, compound 017-01 (143.6 mg, 724.06 mmol, 1.0 eq), 1 (150.0 mg, 724.06 µmol, 1.0 eq), HATU (330.4 mg, 868.88 µmol, 1.2 eq), and DIEA (467.9 mg, 3.62 mmol, 5.0 eq) were dissolved in 2 mL DMF, and the reaction system was stirred for 16 h. The reaction process was monitored by liquid chromatography-mass spectrometry. After the reaction was completed, about 50 mL of water was added to the reaction solution, and then extracted with EtOAc (30 mL) three times, the organic phases were combined and washed once with about 50 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography, eluted with a gradient of 0% - 50% ethyl acetate / petroleum ether mobile phase, and the resulting fractions were concentrated under reduced pressure to remove the solvent to obtain compound 017-02 (colorless oil, 157 mg, yield 56.0%).
[0195] Step 2
[0196]
[0197] At 25 °C, compound 017-02 (157 mg, 405.25 µmol, 1.0 eq) was dissolved in 2 mL of DCM, and 1 mL of TFA was added. The mixture was stirred for about 2 h, and the reaction process was monitored by TLC. After the reaction was completed, the solvent was removed by concentration under reduced pressure, and the residue 017-03 (116 mg) was directly used in the next step.
[0198] Step 3
[0199]
[0200] At 25 °C, compound 017-03 (116 mg, 403.76 µmol, 1.0 eq), 2 (57.6 mg, 403.76 µmol, 1.0 eq) and Cs2CO3 (394.7 mg, 1.21 mmol, 3.0 eq) were dissolved in 2 mL DMF, and the reaction system was placed in a 120 °C oil bath and stirred for about 3 h. The reaction process was monitored by liquid quality control. After the reaction was completed and cooled to room temperature, about 50 mL of water was added to the reaction solution, and then extracted with EtOAc (30 mL) three times, the organic phases were combined and washed once with about 50 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by high pressure preparation to obtain product 017 (44.8 mg, yield 39.4%, purity 99.5%).
[0201] MS (ESI, m / z): 394.2 [M+H] + .
[0202] 1 H NMR (600 MHz, DMSO) δ8.18-8.13(m, 1H), 7.84-7.61 (m, 3H), 7.52-7.41 (m, 1H), 6.64-6.56 (m, 1H), 5.14-4.90 (m, 2H), 4.30-4.27 (m, 1H), 3.97-3.94 (m, 1H),
[0203] 3.63-3.43 (m, 2H), 2.44-2.22 (m, 6H), 2.03-1.90 (m, 1H)
[0204] The following compounds were synthesized as above:
[0205]
[0206] Example 6
[0207] Compound 024: Preparation of (5-(4,6-dimethylpyrimidin-2-yl)-2,5-diazabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone
[0208]
[0209] first step
[0210]
[0211] At 25 °C, compound 024-01 (153.7 mg, 724.06 mmol, 1.0 eq), 1 (150.0 mg, 724.06 µmol, 1.0 eq), HATU (330.4 mg, 868.88 µmol, 1.2 eq), and DIEA (467.9 mg, 3.62 mmol, 5.0 eq) were dissolved in 2 mL DMF, and the reaction system was stirred for 16 h. The reaction process was monitored by liquid chromatography-mass spectrometry. After the reaction was completed, about 50 mL of water was added to the reaction solution, and then extracted with EtOAc (30 mL) three times, the organic phases were combined and washed once with about 50 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography, eluting with a gradient of 0% - 40% ethyl acetate / petroleum ether mobile phase, and the resulting fractions were concentrated under reduced pressure to give compound 024-02 (colorless oil, 212 mg, yield 73.0%).
[0212] Step 2
[0213]
[0214] At 25 °C, compound 024-02 (212 mg, 528.10 µmol, 1.0 eq) was dissolved in 2 mL of DCM, and 1 mL of TFA was added. The mixture was stirred for about 2 h, and the reaction process was monitored by TLC. After the reaction, the residue 024-03 (217.8 mg) was obtained by concentration under reduced pressure and used directly in the next step.
[0215] Step 3
[0216]
[0217] At 25 °C, compound 024-03 (217.8 mg, 524.38 µmol, 1.0 eq), 1 (74.8 mg, 524.38 µmol, 1.0 eq) and Cs2CO3 (512.6 mg, 1.57 mmol, 3.0 eq) were dissolved in 2 mL DMF, and the reaction system was placed in a 120 °C oil bath and stirred for about 2.5 h. The reaction process was monitored by liquid quality control. After the reaction was completed and cooled to room temperature, about 50 mL of water was added to the reaction solution, and then extracted with EtOAc (30 mL) three times, the organic phases were combined and washed once with about 50 mL of saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by high pressure preparation to obtain product 024 (56.2 mg, yield 26.3%).
[0218] MS (ESI, m / z): 408.25 [M+H] + .
[0219] 1 H NMR (600 MHz, DMSO) δ 8.20-8.17 (m, 1H), 8.05-7.93(m, 1H), 7.87-7.78 (m, 1H), 7.74-7.66 (m, 1H), 7.50-7.39 (m, 1H), 6.64(s, 1H), 5.13-4.79(m, 2H), 3.88-3.41 (m, 4H), 2.36-2.28 (m, 6H), 1.96-1.76 (m, 4H)
[0220] The following compounds were synthesized as above:
[0221]
[0222]
[0223] Test Example 1. Determination of the inhibitory activity of compounds on OX1 & PFSK-1 (OX2) receptors
[0224] 1. Cell Information
[0225]
[0226] 1.1 In this study, stably transfected cells expressing OX1 receptor and PFSK-1 (OX2) cells were incubated with different concentrations of test compounds, and the inhibition of the compounds on OX1 & OX2 receptors was determined using the FLIPR CALCIUM 6 ASSAY KIT kit.
[0227] 1.2. OX1-CHO cell line was cultured in F12 medium containing 10% fetal bovine serum and 0.2 mg / mL Hygromycin B, and PFSK-1 (OX2) was cultured in 1640 medium containing 10% fetal bovine serum at 37°C and 5% carbon dioxide concentration.
[0228] 1.3. Cell passaging: Remove the old culture medium and wash once with PBS, then add 1 mL of TrypLE™ Express solution and incubate at 37℃ for about 2 min. When the cells detach from the bottom of the dish, add about 5 mL of complete culture medium preheated at 37℃. Gently pipette the cell suspension to separate the aggregated cells. Transfer the cell suspension to a sterile centrifuge tube and centrifuge at 1000 rpm for 5 min.
[0229] 1.4. In order to maintain the physiological activity of cells, the cell confluence degree was controlled at about 80%.
[0230] 2. Experimental Procedure
[0231] 2.1 Cell plating: OX1&PFSK-1(OX2)-CHO cells were digested and collected, resuspended and counted, and then inoculated into 384-well cell plates at a density of 1.2×10 4 cells / 25 μL / well. Then place the cell plate in a 37°C, 5% CO2 incubator for about 16-20 hours;
[0232] 2.2 Day 2: Prepare the Assay Buffer according to the instructions of the FLIPR Calcium 6 Assay Kit. Freeze and thaw 20× Compound A to room temperature, dilute it with Assay buffer to 1× loading buffer, and keep it at room temperature for later use;
[0233] 2.3 Remove the culture medium from the cell plate, quickly add 35 μL 1× loading buffer to each well, centrifuge and incubate the cell plate at 37°C in the dark for 120 min;
[0234] 2.4 Prepare the working solution of positive compound and test compound, transfer 5 μL to the corresponding cell wells, and incubate at 37°C in the dark for 30 min;
[0235] 2.5 Prepare agonist and transfer 20 μL / well to a 384-well compound source plate;
[0236] 2.6 Place the cell plate, source plate and pipette tip in the corresponding position of the FLIPR instrument. Use the FLIPR Tetra to add 10 μL of the diluted compound in step 5 to each experimental well and collect data at a wavelength of 515 nm-575 nm.
[0237] 2.7 Plot the signal value against the compound concentration and use the GraphPad Prism software nonlinear regression method to fit the IC curve 50 calculate.
[0238] 3. Data Analysis
[0239] 1) Z' factor = 1-3*(SD Max+SD Min) / (AVG Max- AVG Min);
[0240] 2) CV Max = (SD Max / AVG Max)*100%;
[0241] 3) CV Min = (SD Min / AVG Min)*100%;
[0242] 4) S / B = Signal / Background;
[0243] 5) Calculate compound IC using GraphPad nonlinear fitting formula 50 :
[0244] Y=Bottom + (Top-Bottom) / (1+10^((LogIC 50 -X)*HillSlope))
[0245] 6) % Inhibition rate formula:
[0246]
[0247] Mean values of positive controls.
[0248] Mean values of negative controls (DMSO).
[0249] 4. Test results:
[0250] Among them, the positive compound is Seltorexant, and its structure is shown below:
[0251]
[0252]
[0253] Selection ratio = molecule inhibitory activity on OX1R (nM) / molecule inhibitory activity on OX2R (nM). The experimental data were completed within the same test batch.
[0254] 5. Experimental Conclusion
[0255] The compounds of the present application have a good inhibitory effect on OX2R, and the inhibitory effect is significantly better than that of OX1R, indicating that the compounds of the present application have excellent OX2R selectivity and are expected to have higher efficacy.
[0256] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A compound, its crystal form or pharmaceutically acceptable salt, characterized in that: The compound is selected from the group consisting of: 。 2. A pharmaceutical composition, characterized in that: The composition comprises: (i) the compound according to claim 1, its crystalline form or pharmaceutically acceptable salt; and (ii) a pharmaceutically acceptable carrier, adjuvant or vehicle.
3. The use of the compound according to claim 1 or the pharmaceutical composition according to claim 2, characterized in that: Used for preparing drugs for treating and / or preventing diseases related to orexin.
4. The use according to claim 3, characterized in that The drug is a selective OX2R inhibitor.
